Mechanism of Exercise-Associated Plasma Exosomes in the Regulation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106066

Enrollment

Unknown

Registered

2025-07-16

Start date

2025-09-01

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease

Interventions

Exercise Group:Perform aerobic exercise four or more times per week, with each session lasting no less than one hour.

Control Group:Adhere to usual lifestyle habits, avoiding all exercise exceeding 15 minutes of low intensity and refraining from any moderate-intensity activity throughout the study.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with MASLD at Nanjing Second Hospital after December 1, 2024; 2. Aged 18–60 years; 3. MASLD diagnosis based on the *Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Non-Alcoholic) Fatty Liver Disease (2024 Edition)*, defined as:Imaging-confirmed hepatic steatosis and/or histopathological evidence of =5% macrovesicular steatosis,Combined with obesity and/or type 2 diabetes, metabolic syndrome, or at least one metabolic cardiovascular risk factor; 4. No prior regular exercise habits; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Age 60 years; 2. History of regular exercise habits, defined as:aerobic activity (>2 sessions/week at any intensity), or strength/resistance training (>2 sessions/week); 3. Comorbid chronic diseases (other than metabolic disorders*: obesity, diabetes, fatty liver, or dyslipidemia); 4. Musculoskeletal disorders impairing adherence to exercise; 5. Active malignancy (any type); 6. Pregnancy, lactation, or planned pregnancy; 7. Unwillingness to participate or inability to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase;Aspartate Aminotransferase;Total Triglycerides;Total Cholesterol;Low-Density Lipoprotein Cholesterol;High-Density Lipoprotein Cholesterol;Exosome;Weight;Human body composition analysis; Body Mass Index;	—

Secondary

Measure	Time frame
Waist circumference;Hip circumference;Height;Heart rate;	—

Countries

China

Contacts

Public ContactYongfeng Yang

The Second Hospital of Nanjing

yyf1997@163.com+86 139 5199 0210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026